
The biotech sector is notoriously volatile, influenced by clinical trial results and regulatory approvals. Thus, investing in biotech Exchange-Traded Funds (ETFs) provides investors with a strategic opportunity to gain exposure to cutting-edge healthcare innovations without the risks associated with individual stock picking.
Below I have highlighted three biotech ETFs: iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT).